A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know
Wassil exercised options at a steep discount and surrendered shares for tax withholding, maintaining a 0.1% ownership stake following the transactions.
Overview
Jim Wassil, Chief Operating Officer of Vaxcyte, Inc. (NASDAQ:PCVX), reported the sale of 6,182 shares of common stock on August 31 and September 1, totaling $378,000, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($61.12); post-transaction value based on the September 2 market close ($61.58).
Details
Vaxcyte, Inc. is a clinical-stage biotechnology enterprise headquartered in San Carlos with 507 employees, focused on developing next-generation protein-based vaccines addressing significant gaps in infectious disease prevention. The company's strategic approach leverages advanced conjugate vaccine technology to create multi-valent formulations with enhanced immunogenicity and broader pathogen coverage compared to existing therapeutic options. With a market capitalization of $9.0 billion and a one-year share price appreciation of 95%, Vaxcyte represents investor confidence in its clinical pipeline and the substantial market opportunity within the global vaccine sector.
Source
Originally published at www.fool.com.